Research To Practice | Oncology Videos

Inside the Issue: Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity Management | Faculty Presentation 2: Tolerability and Other Practical Considerations with Bispecific Antibodies for MM CME information and select publications

Featuring perspectives from Dr Matthew Gubens, including the following topics: Investigator perspectives on emerging findings with immunotherapy for resectable non-small cell lung cancer (NSCLC) (0:00) Immunotherapy for early-stage unresectable disease (7:51) First-line therapy for patients with metastatic NSCLC with and without targetable mutations (17:46) Current and potential roles of antibody-drug conjugates in the treatment of NSCLC (21:55) Emerging biomarkers in small cell lung cancer research (26:45) CME information and select publications

Featuring a slide presentation and related discussion from Dr Matthew Gubens, including the following topics: Early-stage non-small cell lung cancer (NSCLC) with an EGFR mutation (0:00) Management of metastatic NSCLC with an EGFR mutation (6:34) Prognostic and predictive implications of plasma circulating tumor DNA for first-line therapy for metastatic NSCLC with a HER2 mutation (12:18) Emerging findings with immunotherapy for resectable NSCLC (13:36) Immunotherapy for early-stage unresectable disease (23:14) Emerging data with immunotherapy for metastatic NSCLC (26:00) Tumor treating fields with standard therapy for metastatic NSCLC after platinum failure (35:38) Patient-reported outcomes and emerging results with durvalumab-based therapies for extensive-stage small cell lung cancer (44:51) CME information and select publications

Featuring perspectives from Dr Omid Hamid and Dr Evan J Lipson, including the following topics: Introduction: Immunology of Melanoma (0:00) Melanoma (8:26) Cutaneous Squamous Cell Carcinoma (43:15) Basal Cell Carcinoma and Merkel Cell Carcinoma (52:55) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers | Faculty Presentation 2: Localized Melanoma and Other Types of Skin Cancer — Evan J Lipson, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers | Faculty Presentation 1: Metastatic Melanoma — Omid Hamid, MD CME information and select publications

Featuring a slide presentation and related discussion from Dr Philip A Philip, including the following topics: Comprehensive biomarker analysis for patients diagnosed with colorectal cancer (CRC) (0:00) Selection and sequencing of systemic therapy for patients with metastatic CRC (11:48) Prevalence of claudin-18.2 in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer (22:31) Emerging systemic therapies for hepatocellular carcinoma (24:49) Management of advanced biliary tract cancers (30:04) Activity of NALIRIFOX (liposomal irinotecan/oxaliplatin/leucovorin/fluorouracil) for treatment-naïve metastatic pancreatic cancer (35:35) CME information and select publications

Featuring an interview with Dr Philip A Philip, including the following topics: Comprehensive biomarker analysis for patients diagnosed with colorectal cancer (CRC) (0:00) Selection of first-line therapy for patients with metastatic CRC (mCRC) (7:51) Therapeutic options for patients with HER2-positive mCRC (10:10) Patient selection for regorafenib and/or TAS-102 with or without bevacizumab for mCRC (16:57) Selection and sequencing of therapeutic options for patients with unresectable or metastatic gastric or gastroesophageal junction cancer (19:52) Current and emerging immune checkpoint inhibitor-based combinations for hepatocellular carcinoma (24:51) First- and later-line therapy for patients with advanced biliary tract cancers (33:17) Activity of NALIRIFOX (liposomal irinotecan/oxaliplatin/leucovorin/fluorouracil) for treatment-naïve metastatic pancreatic cancer (36:12) CME information and select publications

Featuring perspectives from Dr Neeraj Agarwal, Dr Emmanuel S Antonarakis, Prof Karim Fizazi and Dr Susan F Slovin, including the following topics: Introduction: Current landscape of prostate cancer treatment (0:00) Relevance of homologous recombination repair mutations in castration-resistant prostate cancer: Treatment with PARP inhibitors as monotherapy — Dr Antonarakis (12:33) Phase III PROpel and MAGNITUDE trials — Dr Slovin (35:44) PARP inhibitor combination treatments for advanced prostate cancer — Dr Agarwal (57:08) Future directions in the use of PARP inhibitors for prostate cancer — Prof Fizazi (1:23:49) Journal Club (1:35:53) Case discussions (2:11:57) CME information and select publications

Featuring a slide presentation and related discussion from Dr Floor J Backes, including the following topics: Recent updates from ASCO 2023 in the management of ovarian cancer (0:00) Recent updates from ASCO 2023 in the management of endometrial cancer (36:08) Recent updates from ASCO 2023 in the management of cervical cancer (41:48) CME information and select publications